COMBINATION THERAPY FOR PANCREATIC CANCER USING AN ANTIGENIC PEPTIDE AND CHEMOTHERAPEUTIC AGENT NAMELY GEMCITABINE

摘要

Disclosed is a an anti-cancer agent for treating cancer in a subject comprising (i) in combination with (ii); (i) one or more peptides inducing CTL selected from the group consisting of; (a) one or more peptides having the amino acid sequence selected from the group consisting of RFVPDGNRI (SEQ ID NO: 1), VYSSEEAEL (SEQ ID NO: 2), GYRIYDVVL (SEQ ID NO: 3), SYMISYAGM (SEQ ID NO: 4), KWEFPRDRL (SEQ ID NO: 5), and DFLTLEHLI (SEQ ID NO: 6), (b) the peptide of (a), in which 1, 2, or several amino acids are substituted, deleted, or added, and wherein said peptide has cytotoxic T cell inducibility; (c) the peptide of (b), wherein the second amino acid from the N-terminus is phenylalanine, tyrosine, methionine, or tryptophan; (d) the peptide of (b) or (c) , wherein the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine; (e) one or more peptides having the amino acid sequence selected from the group consisting of AMFFWLLLV (SEQ ID NO: 7), VIAMFFWLL (SEQ ID NO: 8), AVIAMFFWL (SEQ ID NO: 9), KLIEIGVQT (SEQ ID NO: 10), YMISYAGMV (SEQ ID NO: 11), IQSDVWSFGV (SEQ ID NO: 12) and VLAMFFWLL (SEQ ID NO: 13); (f) the peptide of (e), in which 1, 2, or several amino acids are substituted, deleted, or added, and wherein said peptide has cytotoxic T cell inducibility; (g) the peptide of (f), wherein the second amino acid from the N terminus is leucine or methionine; and (h) the peptide of (f) or (g), wherein the C-terminal amino acid is valine or leucine, (ii) one or more chemotherapeutic agents selected from the group consisting of gemcitabine, a pharmaceutically acceptable salt thereof, and a prodrug thereof.